Alkermes up as skin cancer drug gets 'Innovation Passport' tag from UK regulator

Alkermes

17/01/2023 16:20

** Alkermes plc's shares  ALKS.O  rise 4.4% to $28.5 
    ** Drugmaker says it experimental drug to treat a rare type
of skin cancer, mucosal melanoma, has been granted "Innovation
Passport" designation by UK health regulator
    ** The designation marks ALKS's drug candidate entry to
Innovative Licensing and Access Pathway program, which helps to
accelerate the time required by drugs treating life-threatening
diseases to reach market
    ** ALKS up ~12% last year
 (Reporting by Khushi Mandowara in Bengaluru)
 ((Khushi.Mandowara@thomsonreuters.com;))